CareDx
CDNA

$27.10

0.11%

Market Cap: $1.43B

About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

Employees: 643

Healthcare Medical Laboratories

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

150% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $602K

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

40% more capital invested

Capital invested by funds: $593M [Q1] → $830M (+$238M) [Q2]

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

6% more funds holding

Funds holding: 145 [Q1] → 153 (+8) [Q2]

5.4% less ownership

Funds ownership: 108.1% [Q1] → 102.7% (-5.4%) [Q2]

12% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 57

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

41%

downside

Avg. target

$28

5%

upside

High target

$40

48%

upside

5 analyst ratings

4 positive

80%

0 neutral

0%

1 negative

20%

Wells Fargo Brandon Couillard 36% 1-year accuracy 4 / 11 met price target	3%upside $28	Underweight Initiated	27 Aug 2024
BTIG Sung Ji Nam 54% 1-year accuracy 7 / 13 met price target	48%upside $40	Buy Upgraded	19 Aug 2024
Goldman Sachs Matthew Sykes 67% 1-year accuracy 31 / 46 met price target	4%downside $26	Buy Maintained	1 Aug 2024
Craig-Hallum Connor Chamberlain 100% 1-year accuracy 3 / 3 met price target	18%upside $32	Buy Maintained	1 Aug 2024
Goldman Sachs Matthew Sykes 67% 1-year accuracy 31 / 46 met price target	41%downside $16	Buy Maintained	17 Jul 2024

See Analyst Rankings

Financial journalist opinion

CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to retire a draft LCD that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection. Combined with the February 2024 removal of restrictive language in the accompanying Billing Article and based on discussions with CMS, CareDx believes that longstanding coverage.

CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing

Zacks Investment Research

CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?

CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research

CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?

CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks Investment Research

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

CareDx, Inc. (CDNA) Q2 2024 Earnings Call Transcript

CareDx, Inc. (NASDAQ:CDNA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and CEO Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Alex Johnson - President, Patient and Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Kayla Hostetler - Jefferies Prashant Kota - Goldman Sachs Andrew Cooper - Raymond James Nathan Kariko - Stephens Vivian Bais - BTIG Yi Chen - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good day, everyone.

CareDx, Inc. (CDNA) Q2 2024 Earnings Call Transcript

Zacks Investment Research

CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates

CareDx (CDNA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.18 per share a year ago.

CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates

CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Reported total revenue of $92.3 million, an increase of 31% year-over-year. Grew Testing Services volume to 43,700 tests, an increase of 17% year-over-year. Reported GAAP net loss of $1.4 million, non-GAAP net income of $13.6 million, and positive adjusted EBITDA of $12.9 million, a significant improvement from th.

CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)

NEW YORK , July 16, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CareDx, Inc. (NASDAQ: CDNA) on behalf of the company's shareholders. The investigation seeks to determine whether CareDx's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)

CareDx to Report Second Quarter 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report Second Quarter 2024 Financial Results

Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and.

Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

See News Rankings